Welcome to our dedicated page for Smith & Nephew news (Ticker: SNN), a resource for investors and traders seeking the latest updates and insights on Smith & Nephew stock.
Smith & Nephew plc (NYSE: SNN, LSE: SN) is a global medical technology business whose news flow reflects activity across orthopaedics, sports medicine & ENT, and advanced wound management. Company announcements frequently highlight new product launches, clinical evidence, strategic partnerships and portfolio updates that are relevant to surgeons, healthcare providers and investors following SNN stock.
Recent news has showcased advanced wound management innovations, such as clinical data on the PICO◊ Single Use Negative Pressure Wound Therapy System demonstrating reductions in wound dehiscence, length of stay and costs versus an alternative device in orthopaedic and cardiovascular surgery, and studies on the ALLEVYN™ COMPLETE CARE 5-Layer Foam Dressing describing its mechanism in absorbing and dissipating shear forces linked to pressure injury risk.
In Sports Medicine, Smith+Nephew news items have covered the REGENETEN◊ Bioinductive Implant, including randomized controlled trial results and expanded indications to extra-articular ligament injuries, as well as updates on the CARTIHEAL◊ AGILI-C◊ Cartilage Repair Implant, including the establishment of a Category I CPT code recognising its clinical significance and adoption. Announcements also describe launches such as the Q-FIX™ KNOTLESS All-Suture Anchor and the CENTRIO Platelet-Rich-Plasma System for chronic exuding wounds.
Orthopaedics-related releases include the launch of the TRIGEN™ MAX Tibia Nailing System for tibial fractures and the expansion of CORIOGRAPH™ Pre-Op Planning and Modeling Services to total shoulder arthroplasty, alongside references to the AETOS◊ Shoulder System. Strategic and investor-focused news covers topics such as the RISE strategy, medium-term financial targets, and acquisitions like Integrity Orthopaedics and its Tendon Seam™ rotator cuff repair technology.
Visitors to this SNN news page can review these updates in one place, tracking how Smith & Nephew presents clinical data, regulatory milestones, portfolio expansions, partnerships with organisations such as UFC and Wimbledon, and capital markets communications that shape the company’s profile in the global medical technology sector.
Smith+Nephew (LSE:SN, NYSE:SNN) has signed a co-marketing agreement with JointVue for its OrthoSonic™ 3D Surgery Planning Technology, the only ultrasound device currently on the market to deliver 3D preoperative planning. This technology will be used with Smith+Nephew's CORI◊ Surgical System for robotic-assisted knee arthroplasty, allowing surgeons to create personalized surgical plans.
The combination offers an ideal solution for Ambulatory Surgery Centers (ASCs) where OR space is JointVue's technology provides a radiation-free, automated planning tool that generates a 3D plan within minutes, guiding surgeons to tailor procedures uniquely to each patient. This partnership expands the imaging modalities available to Smith+Nephew customers for pre-op robotic planning, potentially improving patient satisfaction and operating room efficiency.
Smith+Nephew has launched the LEGION Hinged Knee (HK) System with OXINIUM Technology in the United States. This system, part of the LEGION Total Knee System, is designed to provide a natural range of motion and allows surgeons to transition intraoperatively from a constrained revision knee implant to a hinged assembly. The OXINIUM Technology offers several advantages over traditional materials, including:
- Lower inflammatory response
- Superior wear resistance
- Reduced surface damage
- Fewer signs of corrosion damage
These benefits help mitigate common risk factors associated with revision procedures. The LEGION revision with OXINIUM Technology has demonstrated the lowest risk of re-revision compared to the class average.
Smith+Nephew (LSE:SN, NYSE:SNN) has announced positive feedback from the first surgical cases using its new CATALYSTEM Primary Hip System. The system, designed for primary hip surgery, features a triple-taper stem design with uniform proximal loading and reduced distal stem geometry, making it ideal for anterior approach procedures. Key features include:
1. RI.HIP NAVIGATION for enhanced patient outcomes
2. Proprietary ACCUBROACH Technology for reproducible stem seating
3. User-friendly instruments suitable for direct anterior approach
4. Superior cutting and precise feel for rotational stability
Surgeons praised the system's precision, efficiency, and anatomical fit. The CATALYSTEM Primary Hip System represents a significant advancement in hip replacement technology, combining advanced technology with patient personalization.
Cadence, a leading provider of contract manufacturing solutions for MedTech and Pharma markets, has appointed Bob White to its Board of Directors. White brings over 25 years of business leadership experience, with a focus on operational excellence, technological innovation, and strategic growth. He previously served as Executive Vice President and Group President at Medtronic, managing five global businesses across 70 countries. White's experience includes:
- Leading 25,000 employees and 13 manufacturing facilities
- Achieving consistent above-market growth
- Completing seven acquisitions, a joint venture, and a multi-billion-dollar divestiture
White currently serves as an Independent Director for Smith & Nephew (NYSE: SNN) and holds an MBA from Case Western Reserve University. His appointment is expected to contribute significantly to Cadence's strategic goals and market approach.
Smith+Nephew (NYSE:SNN) has launched TOTAL ANKLE Patient-Matched Guides for total ankle replacement (TAR) procedures. This innovative system, developed in partnership with 3D Systems, offers surgeons a predictable and efficient option for planning and performing TAR. Key benefits include:
1. Predictability in the OR with integrated fluoroscopic cues and all-in-one instrumentation
2. Accuracy to plan through fluoroscopic alignment cues and standard instrumentation
3. User-friendly design providing tactile feedback and precise patient fit
The guides are compatible with Smith+Nephew's CADENCE and SALTO TALARIS Total Ankle Systems. This launch strengthens the company's position in the growing TAR market, which is expected to see a CAGR of 6.98% through 2031.
InfuSystem Holdings, Inc. (NYSE American: INFU) has announced a three-year distribution agreement with Smith+Nephew for its negative pressure wound therapy (NPWT) system. InfuSystem will offer Smith+Nephew's advanced RENASYS◊ EDGE NPWT system, a lightweight and compact option for home-based care of chronic wounds.
The partnership leverages InfuSystem's Patient Services platform and network of over 800 in-network health insurance providers, covering 96% of the U.S. population. This collaboration aims to increase patient access to the RENASYS EDGE technology and create new revenue opportunities for both companies.
InfuSystem's CEO, Richard DiIorio, emphasized the company's ability to provide customized solutions and high-value services around partners' products, making them an attractive secondary distribution partner for Smith+Nephew's NPWT system.
Smith+Nephew (LSE:SN, NYSE:SNN) has announced an exclusive digital and advanced analytics collaboration with Healthcare Outcomes Performance Company (HOPCo) to enhance solutions for Ambulatory Surgery Center (ASC) customers, physicians, and patients. The partnership integrates HOPCo's AI-powered myrecovery platform and Vitals platform with Smith+Nephew's CORI Surgical System.
This collaboration aims to provide comprehensive technology for all musculoskeletal procedures in ASCs, offering patient engagement tools, remote care management, and critical quality outcome metrics. The integration will enhance analytics for personalized surgical planning, intra-operative decision-making, and patient-reported outcomes tracking, potentially improving patient outcomes and reducing costs in value-based care settings.
Smith+Nephew (NYSE:SNN) has received 510(k) clearance for its new CATALYSTEM Primary Hip System from the FDA. This system is designed to meet the evolving demands of primary hip surgery, including the increased adoption of anterior approach procedures and the expanding role of Ambulatory Surgery Centers (ASCs).
Key features of the CATALYSTEM system include:
- A triple-taper stem design with uniform proximal loading
- Reduced distal stem geometry and shorter lengths
- Proprietary ACCUBROACH Technology for reproducibility between broach and implant
- Compatibility with the CORI Surgical System
The system aims to provide precision fit, confidence in stem seating, and surgical efficiencies, making it suitable for diverse patient anatomies and various surgical approaches.
Smith+Nephew has launched the Orthopaedics for All initiative, creating a global advisory board to promote diversity, equity, and inclusion in orthopaedic surgery. The initiative aims to address the significant gender disparity in the field, where only 15% of orthopaedic residents and 7.4% of practicing surgeons in the U.S. are women. The board comprises around 20 leading female surgeons with a minimum of two years of post-fellowship experience. Smith+Nephew's initiative also includes partnerships, like with the Perry Initiative, to inspire young women to pursue careers in orthopaedics.
Smith+Nephew (SNN), a global leader in medical technology, has announced its sponsorship of tennis players at Wimbledon 2024, aiming to spotlight its advanced Sports Medicine solutions. The company offers innovative solutions for common tennis injuries like rotator cuff and meniscus tears. Its REGENETEN Bioinductive Implant for rotator cuff repair has been used in over 100,000 procedures globally, showing significant clinical success. The FAST-FIX Family of meniscal repair solutions boasts a 30-year track record, aiding hundreds of thousands of patients with an 88% success rate in all-inside repairs. Smith+Nephew's sponsorship aligns with its mission to help individuals recover from injuries and return to their favorite activities.